On Thursday, Viatris Inc. (NASDAQ:VTRS) reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis. Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company’s portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia. Related: Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs. Generic net sales of $1.42 billion reflect strong growth from new product ...